Thrombomodulin: A Bifunctional Modulator of Inflammation and Coagulation in Sepsis

Takayuki Okamoto,1 Hironobu Tanigami,2 Koji Suzuki,1,3 and Motomu Shimaoka1,2

1 Department of Molecular Pathobiology and Cell Adhesion Biology, Graduate School of Medicine, Mie University, 2-174 Edobashi, Tsu 514-8507, Japan
2 Department of Anesthesiology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan
3 Faculty of Pharmaceutical Science, Suzuka University of Medical Science, 3500-3 Minamitamagaki-cho, Suzuka City 513-8679, Japan

Correspondence should be addressed to Motomu Shimaoka, shimaoka@idi.harvard.edu

Received 30 September 2011; Revised 1 December 2011; Accepted 1 December 2011

Academic Editor: Edward A. Abraham

Copyright © 2012 Takayuki Okamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Deregulated interplay between inflammation and coagulation plays a pivotal role in the pathogenesis of sepsis. Therapeutic approaches that simultaneously target both inflammation and coagulation hold great promise for the treatment of sepsis. Thrombomodulin is an endogenous anticoagulant protein that, in cooperation with protein C and thrombin-activatable fibrinolysis inhibitor, serves to maintain the endothelial microenvironment in an anti-inflammatory and anticoagulant state. A recombinant soluble form of thrombomodulin has been approved to treat patients suffering from disseminated intravascular coagulation (DIC) and has thus far shown greater therapeutic potential than heparin. A phase II clinical trial is currently underway in the USA to study the efficacy of thrombomodulin for the treatment of sepsis with DIC complications. This paper focuses on the critical roles that thrombomodulin plays at the intersection of inflammation and coagulation and proposes the possible existence of interactions with integrins via protein C. Finally, we provide a rationale for the clinical application of thrombomodulin for alleviating sepsis.

1. Introduction

Septic shock is a leading cause of death in intensive care units and thus represents a substantial financial burden on the healthcare system in Japan, in the United States, and in many other developed nations [1, 2]. Although the mortality rate of septic shock has tended to gradually decrease during the past decade thanks to significant technological advances in supportive therapies, it remains high and effective specific treatments are still very limited [3]. Uncontrolled and systematically spreading inflammatory responses that are initiated by infection play critical roles in the pathogenesis of septic shock. At sites of uncontrolled inflammation, endothelial cells are damaged, thereby upregulating intercellular-adhesion-molecule-1 (ICAM-1) and vascular-cell-adhesion-molecule-1 (VCAM-1) expression, which not only enables the accumulation of leukocytes but also heightens permeability, thus leading to tissue edema formation. Damaged endothelial cells exhibit morphological abnormalities such as nuclear vacuolation, protrusion, and cytoplasmic fragmentation, thereby being subjected to the detachment from the basement membrane [4]. Furthermore, inflammation deregulates coagulation cascades, thereby inducing intravascular blood coagulation at inflamed endothelial cells, which reflects the tendency of septic shock to manifest various coagulopathies that lead to disseminated intravascular coagulation (DIC) [5].

Current consensus on septic shock pathogenesis holds that dysregulation occurs simultaneously in both the inflammation and coagulation systems, thereby complicating pathogenesis in patients and reducing the therapeutic
effectiveness of targeting either inflammation or coagulation. A better understanding of the crosstalk that occurs between inflammation and coagulation is therefore critical to developing novel, effective treatments for sepsis. Recent investigations have shown that activated protein C (APC), an endogenous anticoagulant protein, possesses both anti-inflammatory and anticoagulant properties. A recombinant form of APC (Drotrecogin alfa-activated (DrotAA)) has been used in the treatment of severe septic shock [6]. In this paper, we focus on another important endogenous anticoagulant protein, thrombomodulin (TM). Recombinant soluble TM (Recomodulin) has been approved in Japan in 2008 for the treatment of DIC resulting from infection and cancer [7–11]. Currently in the USA a phase II clinical trial involving sepsis DIC patients has been completed and subsequent phase III trials are planned. Here, we examine the basic biology of TM with a particular emphasis on its role at the intersection of inflammation and coagulation and then discuss its potential application for septic shock.

2. Crosstalk between Inflammation and Coagulation

Systemic inflammation causes the activation of the coagulation cascades, and, vice versa, the players in the coagulation cascades also possess the abilities to modulate inflammation [12]. The interplays between inflammation and coagulation are at the center of the pathogenesis underlying septic shock (Figure 1) [5, 12]. One of the major pathways in which inflammation augments blood coagulation is the generation of thrombin mediated by tissue factor (TF) that is upregulated on monocytes, macrophages, and endothelial cells [14]. Endotoxin and proinflammatory cytokines (e.g., interleukin-6 (IL-6)) induce the expression of TF, which binds to factor VII (FVII), thus forming the TF/FVIIa complex that activates FX. FXa assembles with FVa, thereby generating a prothrombinase complex on the surface of endothelial cells and monocytes. This prothrombinase complex converts prothrombin to thrombin, which in turn converts fibrinogen to fibrin, and thereby leads to fibrin formation and platelet activation and aggregation. In addition, inflammation impairs functions of important anticoagulant pathways that are governed by antithrombin, protein C, and tissue factor pathway inhibitor (TFPI). Conversely, inflammation is modified by important players in coagulation and anti-coagulation pathways such as thrombin, antithrombin, thrombomodulin, and protein C as well as fibrinogen and fibrin modulate inflammation [12]. For example, thrombin and other activated coagulation factors exhibit an array of proinflammatory activities via cleavage activation of protease-activated receptors (PARs) [15, 16]. Thrombin induces the following: P-selectin expression in endothelial cells, monocyte and neutrophil chemotaxis [17, 18], leukocyte adhesion molecule expression [15], IL-6 and IL-8 production by endothelial cells [19], and lymphocyte and monocyte activation and proliferation [20, 21].

While thrombin formation is the driving force behind procoagulation and proinflammatory states, thrombin itself remains tightly regulated and under the control of negative feedback loops in which TM plays a critical role in tandem with protein C (Figure 1) [5, 22]. The interaction of TM with thrombin switches thrombin substrate specificity from fibrinogen to protein C [23]. Thrombin, TM, and protein C bind simultaneously, thereby forming a complex on the surface of the endothelium that expresses endothelial cell protein C receptor (EPCR). During the course of complex formation, protein C is converted to its active form: activated PC (APC) [24]. APC subsequently dissociates from the APC-EPCR complex and binds to protein S, in this way forming an APC-protein S complex. The APC-protein S complex dampens not only coagulation, by inactivating FVa and FVIIa, but also inflammation, by inhibiting the production of inflammatory cytokines and the transduction of nuclear-factor-κB (NF-κB) signaling in monocytes [25]. Furthermore, APC suppresses LPS-induced increases in the pulmonary accumulation of leukocytes and in vascular permeability [26]. Therefore, the protein C pathway plays a pivotal role in the negative regulation of coagulation and inflammation. The thrombin-TM complex also activates the thrombin-activatable fibrinolysis inhibitor (TAFI), which in turn inhibits fibrinolysis and inactivates anaphylatoxin C3a and C5a [27, 28]. In addition to acting as a cofactor for APC and TAFI activation, TM has exhibited a wide range of biological activities in maintaining vascular homeostasis (Figure 2) [29].

3. Structure and Domains of Thrombomodulin

Human TM is a single-chain type 1 transmembrane glycoprotein measuring 557-amino acid residues long and containing five extracellular domains (Figure 3) [30, 31]. The N-terminal region of TM comprises about half of the extracellular portion of the molecule and contains a module with a homology to other C-type lectins. Although this domain lacks anticoagulant activity, it plays an important role in mediating anti-inflammatory activities [32, 33].

The next domain of TM contains six epidermal-growth-factor-likeEGF-like) repeats that form an extended stalk in the extracellular part of molecule. This domain showed mitogenic activities on cultured fibroblasts and vascular smooth muscle cells. The activities were mediated via activation of protein kinase C and mitogen-activated protein kinase (MAPK) [34, 35]. The interaction of the EGF5-6 repeats with thrombin has been shown to prevent the binding of procoagulant substrates (e.g., such as FV, fibrinogen) to thrombin [36–39]. These EGF4-6 repeats are required for the activation of protein C, while the EGF3-4 repeats are needed for the activation of TAFI [39–41].

The third domain is a serine/threonine-rich domain bearing potential sites for O-linked glycosylation. This domain supports the attachment of chondroitin sulfate. Biochemical studies have shown that chondroitin sulfate, when attached to TM, enhanced the potency of the latter to activate protein C [42, 43]. In addition, it accelerates the neutralization of thrombin and facilitates the binding of platelet factor 4 (PF4) to protein C [44]. The chondroitin

Biochemical studies have shown that chondroitin sulfate, when attached to TM, enhances the potency of the latter to activate protein C [42, 43]. In addition, it accelerates the neutralization of thrombin and facilitates the binding of platelet factor 4 (PF4) to protein C [44]. The chondroitin sulfate of TM helps in maintaining the balance between coagulation and anticoagulation.
Figure 1: Crosstalk between inflammation and coagulation. Proinflammatory stimulation induces TF expression in monocytes, macrophages, and endothelial cells. TF initiates a coagulation cascade and the FXa-FVa complex converts thrombin. Thrombin induces fibrin formation and activates platelets, monocytes, and endothelial cells through PARs. Thus, thrombin acts to form a positive feedback loop that augments coagulation and inflammation. In a negative feedback loop, the thrombin-TM complex activates protein C and downregulates coagulation and inflammation. APC, in tandem with its cofactor protein S, inactivates FVa and FVIIIa. In addition, the APC-EPCR complex induces anti-inflammatory effects through PARs. Therefore, thrombin, TM, and protein C-EPCR play pivotal roles in the crosstalk that occurs between inflammation and coagulation.

Figure 2: Multiple roles of TM in the maintenance of vascular homeostasis. TM inhibits inflammation, apoptosis, tumor metastasis, thrombin function, adhesion molecule expression, and leukocyte adhesion. Proinflammatory high-mobility group box 1 (HMGB1) is neutralized and degraded by TM.

Sulfate moiety may strengthen the thrombin-TM binding by interacting with the anion binding exosite of thrombin, to which heparin binds. Of note, heparin was shown to inhibit the thrombin-TM binding possibly by competing with the TM chondroitin sulfate moiety for the thrombin exosite [45].

A well-conserved transmembrane domain is typically followed by a short cytoplasmic tail. A cysteine in the cytoplasmic tail is thought to mediate the multimerization of TM [46]. In human-cultured vein endothelial cells, thrombin binding to TM induced signaling events that lead
4. Anticoagulant Properties of Thrombomodulin

TM exerts its anticoagulant activity not only by inhibiting thrombin but also by accelerating APC generation [36, 37, 52, 53]. Upon TM binding, thrombin undergoes a reduction in its affinity to procoagulant substrates [36, 37, 52, 53]. TM directly inhibits most of the procoagulant functions of thrombin including fibrinogen clotting, platelet and EC activation, and FV activation [36, 37]. In addition, TM accelerates the inactivation of thrombin via both antithrombin and protein C inhibitor [54, 55]. TM switches thrombin substrates specificity to protein C [23]. APC suppresses further thrombin formation by proteolytically degrading FVα and FVIIIα. This activity is enhanced by protein S, the cofactor for APC (Figure 1). The anti-inflammatory properties of TM may be partly explained by the concept that the affinity of thrombin for TM is likely much higher than that for other factors in pro- and anticoagulant pathways [23], potentially making TM a scavenging inhibitor of circulating thrombin.

Inflammation has been reported to downregulate TM expression [56]. Tumor necrosis factor-α (TNF-α) induces internalization of TM via endocytosis, thereby reducing its surface expression [57]. Such reduced TM expression at sites of inflammatory injury may exacerbate blood coagulation. Indeed, endothelium-specific deletion of TM in mice caused spontaneous and fatal thrombosis in the arterial and venous vessels [58], indicating that TM may play a role in preventing intravascular thrombus formation.

5. Anti-Inflammatory Effects of Thrombomodulin

5.1. APC-Dependent Mechanisms. TM has been shown to mediate anti-inflammatory activities using APC-dependent and APC-independent mechanisms, depending on the setting [22]. In the APC-dependent mechanism, TM executes its anti-inflammatory activities by enhancing the activation of...
Figure 4: Potential molecular mechanisms by which APC executes anti-inflammatory effects. (a) Caveolin-1 is associated with EPCR in lipid rafts in the absence of protein C or APC. Thrombin cleavage of PAR-1 induces inflammatory responses by coupling receptors to G12/13 and Gq proteins. The occupancy of EPCR by protein C results in the dissociation of EPCR from caveolin-1. Thrombin induces a cytoprotective response by coupling receptors to Gi protein. (b) The APC-EPCR complex cleavage of PAR-1 induces S1P generation and S1P receptor 1 transactivation. Activation of S1P receptor 1 improves endothelial barrier function, thus facilitating the ability of the APC-EPCR complex to exert anti-inflammatory effects.

protein C. The resulting APC downregulates inflammatory cytokine production by decreasing the expression of NF-κB components and inhibiting their nuclear translocation [59–62]. These anti-inflammatory effects are dependent upon APC, EPCR, and PAR-1 [63, 64]. It is thought that protein C and/or APC binding to EPCR results in the coupling of PAR-1 to Gi in endothelial cells (Figure 4(a)) [65–67]. Both PAR-1 and EPCR are known to associate with caveolin-1 in lipid rafts or protein C- or APC-EPCR complexes, leading to caveolin-1 dissociation from EPCR. This process appears to favor anti-inflammatory phenotypes of endothelial cells [68].

APC has been shown to enhance the endothelial barrier function through transactivation of sphingosine-1-phosphate (S1P) receptor signaling (Figure 4(b)) [69, 70]. Improving endothelial barrier function would provide anti-inflammatory effects by reducing leukocyte extravasation to sites of inflammation. Apolipoprotein E receptor 2 (ApoER2) and angiopoietin (Ang)/tie2 signaling pathways have been shown to contribute to the cytoprotective and anti-inflammatory properties of APC [71, 72].

In addition to acting on endothelial cells, APC has been shown to target leukocytes. In one study, APC bound to leukocyte integrins through an RGD motif, thereby inhibiting neutrophil migration into inflamed tissues [73]. In addition, APC was shown to cleave and consequently neutralize the cytotoxicity of extracellular histones released from dying leukocytes [74]. Histone administration resulted in neutrophil margination, microhemorrhage, intravascular thrombosis, and capillary leak of fibrin. Coadministration of APC alleviated lethality of histone. By contrast, histone toxicity was much more pronounced in mice, where the PC pathway was blocked [74].

Reduced levels of PC were found in the majority of patients with sepsis and were associated with higher rates of morbidity and mortality [75, 76]. A controversial PROWESS study showed that treatment with recombinant APC not only lowered the plasma levels of D-dimer and IL-6 but also reduced mortality in patients with severe sepsis [6].

5.2. APC-Independent Mechanisms. TM modulates fibrinolysis and inflammation through thrombin-activatable fibrinolysis inhibitor (TAFI). TAFI is a circulating zymogen that is activated by the thrombin-TM complex [77, 78]. Activated TAFI eliminates lysine residues at the C-terminal end of fibrin, thereby suppressing the incorporation of plasminogen and tissue plasminogen activator (t-PA) into the fibrin clot (Figure 5). Thus, activation of TAFI by TM inhibits fibrinolysis, thereby preventing the resolution of already formed clots. This activity complements the role of TM-induced activated protein C to prevent the formation of new clots, thereby balancing hemostasis [79]. While diminishing fibrinolysis by acting on fibrin, activated TAFI also affects inflammation [77, 78]. TAFIa has been reported to act on, and inactivate, proinflammatory mediators such as the anaphylatoxins complement factors C3a and C5a [80–82], bradykinin, and osteopontin [44, 78].

Independently of APC, TM exhibits anti-inflammatory activities via the EGF domain of TM and the N-terminal
Coagulation

- Thrombin
  - TAFIa
  - TM
  - PF4

Fibrinogen
- Plasminogen
- Thrombin
- Fibrin

Cleaved fibrin
Inactivation
- C3a, C5a, bradykinin, osteopontin

Reduction
- Inhibition of fibrinolysis

Figure 5: TAFIa-dependent modulation of inflammation and fibrinolysis. TAFIa appears to possess anti-inflammatory properties due to its ability to inactivate proinflammatory mediators, C3a, C5a, bradykinin, and osteopontin by removing their C-terminal residues. TAFIa also removes the C-terminal lysines of fibrin, leading to a reduction in the rates of plasmin generation and fibrinolysis. PF4 inhibits the activation of TAFI and enhances the activation of protein C by the TM-thrombin complex.

TM
Unidentified receptor
NF-κB, MAP kinase
Leukocyte adhesion
Proinflammatory effects
- Platelet activation
- Cytokines
- Leukocyte adhesion
- Necrosis

HMGB1 degradation
PAR-1
Thrombin
RAGE

Figure 6: APC- and TAFIa-independent anti-inflammatory effects of TM. Thrombomodulin binds to thrombin, thereby blocking activation of protease-activated receptors. The lectin-like domain binds to, and enhances degradation of, proinflammatory molecule HMGB1. In addition, the lectin-like domain is thought to bind to an unidentified receptor, thereby suppressing MAP kinase and NF-κB activation.

The anti-inflammatory activities of the N-terminal lectin-like domain are thought to act in an APC-independent manner, since this domain is dispensable to APC generation. Mutant mice expressing TM that lacks this lectin-like domain did not show altered in vivo APC generation [33]. However, these mice did exhibit an increased susceptibility to endotoxin-induced sepsis. Endothelial cells isolated from mutant mice exhibited elevated ICAM-1 expression as well as increased ICAM-1-mediated leukocyte adhesion. In good agreement with these findings, a soluble lectin-like N-terminal domain of TM proved sufficiently robust to inhibit TNF-α-induced ERK phosphorylation and restore normal leukocyte adhesion to mutant endothelial cells. In addition, this recombinant lectin-like TM domain also protected cultured endothelial cells from cell death, possibly via modulation of NF-κB pathways, but more likely by serum deprivation [33].

Another anti-inflammatory target of TM is high-mobility group box 1 (HMGB1), a ubiquitously expressed nuclear protein that is released from necrotic cells. Upon being released, HMGB1 binds to the receptor for advanced
glycation end products (RAGE) [85]. HMGB1-RAGE signaling has been implicated in the pathogenesis and/or progression of various clinical disorders, such as infections, sepsis, arthritis, and cancer. The lectin-like domain of TM interferes with HMGB1 binding to RAGE, thereby impairing HMGB1-RAGE signaling [86]. Alternatively, TM may antagonize HMGB1 by enhancing thrombin-mediated proteolytic degradation of HMGB1 [87].

6. Therapeutic Application of TM

The dual ability of TM to suppress both coagulation and inflammation makes this molecule a promising drug candidate for the treatment of DIC and/or septic shock. In order to administer it intravenously, a soluble form of recombinant TM (rhsTM), containing only the extracellular domains, has been developed [88]. Like the membrane-bound native TM, rhsTM retains the ability to bind to thrombin and APC. Administration of rhsTM has been shown to protect rats from TF and endotoxin-induced DIC or lung injury [89–91]. In addition, rhsTM not only reduced compression trauma-induced spinal cord injury by inhibiting leukocyte accumulation and expression of TNF-α [92] but also provided protection against ischemia-reperfusion injury in the canine liver [93] and in the rat kidney [94, 95].

After obtaining promising results in animal experiments, rhsTM (ART-123, Recomodulin) proceeded to clinical trials. The efficacy and safety of rhsTM for the treatment of DIC has been investigated in a multicenter, randomized, double-blind phase III clinical trial [9]. This clinical trial was designed to compare rhsTM (0.06 mg kg$^{-1}$ for 30 min once day) with heparin (8 U kg$^{-1}$ h$^{-1}$ for 24 h) in 234 DIC patients. Their underlying diseases consisted of infection and/or hematologic malignancy. During a 6-day course of treatment, half of the patients received rhsTM, while the rest received heparin. The DIC resolution rate at day 7 was significantly better in patients receiving rhsTM (66.1%) than in those receiving heparin (49.9%). The disappearance rate of bleeding symptoms at day 7 was also better in patients receiving rhsTM (35.2%) than in those receiving heparin (20.9%). Remarkably, in DIC resulting from infection, rhsTM treatment improved the mortality rates at day 28 to a greater degree than did heparin treatment (rhsTM 28.0%; heparin 34.6%). In the case of DIC resulting from hematologic malignancy, the mortality rates were 17.2% for the rhsTM group and 18.0% for the heparin group. Greater decreases in plasma thrombin-antithrombin complex levels and D-dimer levels were observed in patients treated with rhsTM. Importantly, rhsTM treatment showed a better safety profile with a lower incidence of bleeding-related adverse events. In 2008, rhsTM has been approved in Japan for the treatment of DIC. As of May 2011, 4,260 DIC patients (2,588 infections, 1,121 hematologic malignancies, 93 solid tumors, and 458 miscellaneous underlying diseases) were treated with rhsTM, according to the Asahi Kasei Pharma that has marketed this drug in Japan.

Importantly, a retrospective subanalysis that focused only on the 80 patients having infection as the underlying disease [7] confirmed the usefulness of rhsTM in the treatment of DIC associated with infection (DIC resolution rates (rhsTM: 67.5%; heparin: 55.6%) and 28-day mortality rates (rhsTM: 21.4%; heparin: 31.6%). In the USA, a phase II clinical trial involving 750 patients has been completed as of May 2011 that compared rhsTM with placebo for the treatment of sepsis with DIC (NCT00487656), thereby awaiting the results publicized. The Asahi Kasei Pharma America reports that they will proceed to phase III clinical trials.

7. Concluding Remarks

We are beginning to understand that the crosstalk and interplay that occur between inflammation and coagulation together constitute a critical component driving both the pathogenesis and progression of sepsis. Therapeutic approaches targeting both inflammation and coagulation hold great promise for the treatment of patients suffering septic shock. While APC is the first to be successfully administered under a clinical setting, TM is expected to represent the 2nd generation of effective biologic drugs that target both inflammation and coagulation in septic patients.

Conflict of Interests

The authors (T. Okamoto, H. Tanigami, K. Suzuki, and M. Shimaoka) declare no conflict of interest.

References

[1] J. A. Russell, “Management of sepsis,” *The New England Journal of Medicine*, vol. 355, no. 16, pp. 1699–1713, 2006.

[2] G. S. Martin, D. M. Mannino, S. Eaton, and M. Moss, “The epidemiology of sepsis in the United States from 1979 through 2000,” *The New England Journal of Medicine*, vol. 348, no. 16, pp. 1546–1554, 2003.

[3] T. W. Rice and G. R. Bernard, “Therapeutic intervention and targets for sepsis,” *Annual Review of Medicine*, vol. 56, pp. 225–248, 2005.

[4] H. Ait-Oufella, E. Maury, S. Lehoux, B. Guidet, and G. Offenstadt, “The endothelium: physiological functions and role in microcirculatory failure during severe sepsis,” *Intensive Care Medicine*, vol. 36, no. 8, pp. 1286–1298, 2010.

[5] S. Zeerleder, C. E. Hack, and W. A. Wullemijn, “Disseminated intravascular coagulation in sepsis,” *Chest*, vol. 128, no. 4, pp. 2864–2875, 2005.

[6] G. R. Bernard, J. L. Vincent, P. F. Laterre et al., “Efficacy and safety of recombinant human activated protein C for severe sepsis,” *The New England Journal of Medicine*, vol. 344, no. 10, pp. 699–709, 2001.

[7] N. Aikawa, S. Shimazaki, Y. Yamamoto et al., “Thrombomodulin allele in the treatment of infectious patients complicated by disseminated intravascular coagulation: sub-analysis from the phase III trial,” *Shock*, vol. 35, no. 4, pp. 349–354, 2011.

[8] K. Yamakawa, S. Fujimi, T. Mohri et al., “Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study,” *Critical Care*, vol. 15, no. 3, p. R123, 2011.
[40] W. Wang, M. Nagashima, M. Schneider, I. Morser, and M. Nesheim, “Elements of the primary structure of thrombomodulin required for efficient thrombin-activatable fibrinolysis inhibitor activation,” *Journal of Biological Chemistry*, vol. 275, no. 30, pp. 22942–22947, 2000.

[41] C. Wu, P. Y. Kim, R. Manuel et al., “The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFII by the thrombin-thrombomodulin complex,” *Journal of Biological Chemistry*, vol. 284, no. 11, pp. 7059–7067, 2009.

[42] T. Koyama, J. F. Parkinson, P. Sie, N. U. Bang, G. Muller-Berghaus, and K. T. Preissner, “Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III,” *European Journal of Biochemistry*, vol. 198, no. 3, pp. 563–570, 1991.

[43] M. G. Elisen, P. A. Von Dem Borne, B. N. Bouma, and J. C. Meijers, “Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma,” *Blood*, vol. 91, no. 5, pp. 1542–1547, 1998.

[44] L. O. Mosnier, “Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin,” *Journal of Biological Chemistry*, vol. 286, no. 1, pp. 502–510, 2011.

[45] R. De Cristofaro, E. De Candia, and R. Landolfi, “Effect of high- and low-molecular-weight heparins on thrombin-thrombomodulin interaction and protein C activation,” *Circulation*, vol. 98, no. 13, pp. 1297–1301, 1998.

[46] E. M. Conway, B. Nowakowski, and M. Steiner-Mosonyi, “Thrombomodulin lacking the cytoplasmic domain efficiently internalizes thrombin via nonclathrin-coated, pit-mediated endocytosis,” *Journal of Cellular Physiology*, vol. 158, no. 2, pp. 285–298, 1999.

[47] M. David-Dufilho, E. Millanvoye- Van Brussel, G. Topal, L. Walch, A. Brunet, and F. Rendu, “Endothelial thrombomodulin induces Ca²⁺ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II,” *Journal of Biological Chemistry*, vol. 280, no. 43, pp. 35999–36006, 2005.

[48] A. M. Healy, H. B. Rayburn, R. D. Rosenberg, and H. W. Weiler, “Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 3, pp. 850–854, 1995.

[49] B. Isermann, S. B. Hendrickson, M. Zogg et al., “Endothelium-dependent activation of thrombin by protein C: prerequisites, C2 activation, and antithrombin III,” *European Journal of Biochemistry*, vol. 198, no. 3, pp. 563–570, 1991.

[50] E. M. Conway, S. Pollefeyt, J. Cornelissen et al., “A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation,” *Journal of Biological Chemistry*, vol. 264, no. 9, pp. 4872–4876, 1989.

[51] C. T. Esmon, “Molecular events that control the protein C anticoagulant pathway,” *Thrombosis and Haemostasis*, vol. 70, no. 1, pp. 29–35, 1993.

[52] F. J. Castellino, “Human protein C and activated protein C: components of the human anticoagulation system,” *Trends in Cardiovascular Medicine*, vol. 5, no. 2, pp. 55–62, 1995.

[53] L. Yang, C. Manithody, T. D. Walston, S. T. Cooper, and A. R. Rezaie, “Thrombomodulin enhances the reactivity of thrombin with protein C inhibitor by providing both a binding site for the serpin and allosterically modulating the activity of thrombin,” *Journal of Biological Chemistry*, vol. 278, no. 39, pp. 37465–37470, 2003.

[54] K. T. Preissner, U. Delvos, and G. Muller-Berghaus, “Binding of thrombin to thrombomodulin accelerates inhibition of the enzyme by antithrombin III. Evidence for a heparin-independent mechanism,” *Biochemistry*, vol. 26, no. 9, pp. 2521–2528, 1987.

[55] I. Maruyama and P. W. Majerus, “The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombomodulin,” *Journal of Biological Chemistry*, vol. 260, no. 29, pp. 15432–15438, 1985.

[56] K. L. Moore, C. T. Esmon, and N. L. Esmon, “Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture,” *Blood*, vol. 73, no. 1, pp. 159–165, 1989.

[57] B. Isermann, S. B. Hendrickson, M. Zogg et al., “Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis,” *Journal of Clinical Investigation*, vol. 108, no. 4, pp. 537–546, 2001.

[58] B. White, M. Schmidt, C. Murphy et al., “Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line,” *British Journal of Haematology*, vol. 110, no. 1, pp. 130–134, 2000.

[59] D. E. Joyce and B. W. Grinnell, “Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kB,” *Critical Care Medicine*, vol. 30, supplement 5, pp. S288–S293, 2002.

[60] D. E. Joyce, L. Gelbert, A. Ciaccia, B. DeHoff, and B. W. Grinnell, “Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis,” *Journal of Biological Chemistry*, vol. 276, no. 14, pp. 11199–11203, 2001.

[62] C. T. Esmon, “Protein C anticoagulant system-anti-inflammatory effects,” *Seminars in Immunopathology*, vol. 34, no. 1, pp. 127–132, 2012.

[63] M. Riewald, R. J. Petrovan, A. Donner, B. M. Mueller, and W. Ruf, “Activation of endothelial cell protease activated receptor 1 by the protein C pathway,” *Science*, vol. 296, no. 5574, pp. 1880–1882, 2002.

[64] E. I. Kerschen, I. A. Fernandez, B. C. Cooley et al., “Endotoxemia and sepsis mortality reduction by non-anticoagulant-activated protein C,” *Journal of Experimental Medicine*, vol. 204, no. 10, pp. 2439–2448, 2007.

[65] J. S. Bae and A. R. Rezaie, “Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C,” *Journal of Thrombosis and Haemostasis*, vol. 101, no. 3, pp. 513–520, 2009.
protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells,” Blood, vol. 110, no. 12, pp. 3909–3916, 2007.

[67] J. S. Bae and A. R. Rezaie, “Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand,” Thrombosis and Haemostasis, vol. 100, no. 1, pp. 101–109, 2008.

[68] A. R. Rezaie, “Regulation of the protein C anticoagulant and anti-inflammatory pathways,” Current Medicinal Chemistry, vol. 17, no. 19, pp. 2059–2069, 2010.

[69] J. H. Finigan, S. M. Dudek, P. A. Singleton et al., “Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation,” Journal of Biological Chemistry, vol. 280, no. 17, pp. 17286–17293, 2005.

[70] C. Feistritzer and M. Riewald, “Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crosactivation,” Blood, vol. 105, no. 8, pp. 3178–3184, 2005.

[71] X. V. Yang, Y. Banerjee, J. A. Fernández et al., “Activated protein C ligation of ApoER2 (LRP8) causes Dabi-dependent signaling in U937 cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 1, pp. 274–279, 2009.

[72] N. Minhas, M. Xue, K. Fukudome, and C. J. Jackson, “Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function,” EASEB Journal, vol. 24, no. 3, pp. 873–881, 2010.

[73] G. F. Elphick, P. P. Sarangi, Y. M. Hyun et al., “Recombinant human activated protein C inhibits integrin-mediated neutrophil migration,” Blood, vol. 113, no. 17, pp. 4078–4085, 2009.

[74] J. Xu, X. Zhang, R. Pelayo et al., “Extracellular histones are major mediators of death in sepsis,” Nature Medicine, vol. 15, no. 11, pp. 1318–1321, 2009.

[75] F. Fourrier, C. Chopin, J. Goudemand et al., “Septic shock, multiple organ failure, and disseminated intravascular coagulation; compared patterns of antithrombin III, protein C, and protein S deficiencies,” Chest, vol. 101, no. 3, pp. 816–823, 1992.

[76] J. A. Lorente, L. J. Garcia-Frade, L. Landin et al., “Time course of hemostatic abnormalities in sepsis and its relation to outcome,” Chest, vol. 103, no. 5, pp. 1536–1542, 1993.

[77] L. Bajzar, R. Manuel, and M. E. Nesheim, “Purification and characterization of TAFI, a thrombin-activable fibrinolytic inhibitor,” Journal of Biological Chemistry, vol. 270, no. 24, pp. 14477–14484, 1995.

[78] J. Morser, E. C. Gabazza, T. Myles, and L. L. Leung, “What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?” Journal of Thrombosis and Haemostasis, vol. 8, no. 5, pp. 868–876, 2010.

[79] L. O. Mosnier and B. N. Bouma, “Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 11, pp. 2445–2453, 2006.

[80] M. M. Markiewski, R. A. Deangelis, and J. D. Lambris, “Complexity of complement activation in sepsis: crossroads in sepsis research review series,” Journal of Cellular and Molecular Medicine A, vol. 12, no. 6, pp. 2245–2254, 2008.

[81] M. M. Markiewski and J. D. Lambris, “The role of complement in inflammatory diseases from behind the scenes into the spotlight,” American Journal of Pathology, vol. 171, no. 3, pp. 715–727, 2007.

[82] P. A. Ward, “Role of the complement in experimental sepsis,” Journal of Leukocyte Biology, vol. 83, no. 3, pp. 467–470, 2008.

[83] C. Esmon, “Do-all receptor takes on coagulation, inflammation,” Nature Medicine, vol. 11, no. 5, pp. 475–477, 2005.

[84] J. M. Olivot, E. Estebanell, M. Lafay, B. Brohard, M. Aiach, and F. Rendu, “Thrombomodulin prolongs thrombin-induced extracellular signal-regulated kinase phosphorylation and nuclear retention in endothelial cells,” Circulation Research, vol. 88, no. 7, pp. 681–687, 2001.

[85] M. T. Lotze and K. J. Tracey, “High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal,” Nature Reviews Immunology, vol. 5, no. 4, pp. 331–342, 2005.

[86] K. Abeyama, D. M. Stern, Y. Ito et al., “The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1267–1274, 2005.

[87] T. Ito, K. Kawahara, K. Okamoto et al., “Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 10, pp. 1825–1830, 2008.

[88] K. Gomi, M. Zushi, G. Honda et al., “Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice,” Blood, vol. 75, no. 7, pp. 1396–1399, 1990.

[89] M. Mohri, M. Oka, Y. Aoki et al., “Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats,” American Journal of Hematology, vol. 45, no. 4, pp. 298–303, 1994.

[90] Y. Gonda, S. Hirata, K. Saitoh et al., “Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats,” Thrombosis Research, vol. 71, no. 4, pp. 325–335, 1993.

[91] M. Uchiba, K. Okajima, K. Murakami, K. Nawa, H. Okabe, and K. Takatsuki, “Recombinant human soluble thrombomodulin protects ischemic kidneys,” Thrombosis and Haemostasis, vol. 74, no. 5, pp. 1265–1270, 1995.

[92] Y. Taoka, K. Okajima, M. Uchiba, and M. Johno, “Neuroprotection by recombinant thrombomodulin,” Thrombosis and Haemostasis, vol. 83, no. 3, pp. 462–468, 2000.

[93] H. Kaneko, N. Joubara, M. Yoshino et al., “Protective effect of human urinary thrombomodulin on ischemia/reperfusion injury in the canine liver,” European Surgical Research, vol. 32, no. 2, pp. 87–93, 2000.

[94] T. Ozaki, C. Amas, S. Maruyama et al., “Intrarenal administration of recombinant human soluble thrombomodulin ameliorates ischemic acute renal failure,” Nephrology Dialysis Transplantation, vol. 23, no. 1, pp. 110–119, 2008.

[95] A. A. Sharifuddin, R. M. Sandalov, D. T. Berg et al., “Soluble thrombomodulin protects ischemic kidneys,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 524–534, 2009.